Form 4: Amylyx Pharmaceuticals Director Bernhardt Zeiher Granted 25,000 Stock Options

Amylyx Pharmaceuticals, Inc. Director Bernhardt G. Zeiher was granted 25,000 stock options with an exercise price of $5.05, vesting over approximately one year.

Summary

• Bernhardt G. Zeiher, a Director of Amylyx Pharmaceuticals, Inc. (AMLX), was granted 25,000 stock options.
• The options have an exercise price of $5.05 per share.
• The transaction date for this grant was June 5, 2025.
• The options are exercisable immediately upon grant, but subject to vesting conditions.
• The options are set to expire on June 4, 2035.
• The 25,000 shares subject to this option will vest in full upon the earlier of June 5, 2026, or the date of the next annual meeting, contingent on Mr. Zeiher's continuous service to the Issuer.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as it indicates continued alignment of a director's interests with the company's long-term performance through equity compensation. However, it's a routine filing and not indicative of significant new operational or financial developments.

Positives

• The grant of stock options to a director aligns their interests with those of shareholders, incentivizing long-term performance and value creation.
• The options have a 10-year expiration period, providing a long-term incentive for the director.

Future Outlook

The vesting schedule for the granted options, tied to continuous service, indicates an expectation of the director's ongoing involvement and contribution to the company's future performance.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and director compensation packages to attract and retain talent and align their interests with long-term company success.

Comparison to Industry Standards

• The grant of stock options to non-employee directors is a standard compensation mechanism across publicly traded companies, particularly prevalent in growth-oriented sectors like biotechnology.
• The vesting schedule, tied to continued service and annual meetings, is typical for director equity awards, similar to practices observed at companies like Biogen Inc. or Moderna, Inc. for their board members.
• The 10-year expiration period for the options is also a common industry standard, providing ample time for the options to become in-the-money and serve as a long-term incentive.

Related Party Transactions

• The grant of stock options to Bernhardt G. Zeiher, a Director, constitutes a related party transaction as it involves compensation provided by the company to a member of its board.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with shareholder value creation, as the options gain value only if the stock price increases above the exercise price.
• Employees: No direct impact on general employees from this specific filing.

Next Steps

• The options will vest in full upon the earlier of June 5, 2026, or the date of the next annual meeting, subject to the director's continuous service.

Key Dates

Keywords

Amylyx Pharmaceuticals, AMLX, Stock Options, Director Compensation, Insider Transaction, Form 4, Equity Grant, Pharmaceuticals